Takeda Pharmaceutical Company Limited has launched two new drugs in Japan – Rozerem, to treat insomnia, and Metact, for the treatment of type 2 diabetes.
Rozerem works by selectively targeting two melatonin receptors in the brain, MT1 and MT2, which regulate circadian (24-hour) rhythms, including the sleep-wake cycle.
The drug was first approved by the US Food and Drug Administration in July 2005, and is the first and only prescription sleep the medication that is classified as a non-controlled substance, showing no evidence of abuse or dependence.
Metact is a fixed-dose combination tablet of Actos with Metformin, and is the first treatment of this type that has been approved in Japan for type 2 diabetes.
The combined sales of these products are to be estimated several billion yen.
Takeda Pharmaceutical Marketing Division senior vice-president Yasuhiko Yamanaka said that the launch of Rozerem will mark the company’s full-scale entry into the Japanese central nervous system market, one of its core therapeutic areas.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData